Market Brief: New Triple-Combination Therapies Help Boost Lackluster Inhalation Devices Market
The inhalation devices market will reach $12bn by 2023, driven by the rising prevalence of asthma and COPD worldwide. GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim dominate worldwide sales of inhalation products for asthma and COPD, and are facing generic competition. Generics developers and major pharma players are trying to set themselves apart with better drug-delivery devices.
You may also be interested in...
Spire Health Closed A $38M Financing Round To Expand Commercialization Of Respiratory Remote Patient Monitoring Platform
Spire Health plans to use its new financing to expand commercialization of its respiratory remote patient monitoring platform, which combines AI with sensors in “health tags” worn inside clothing.
The global market for ventilators and pulmonary function assessment products is expected to reach $1.7bn by 2022, driven in large part by rising incidences of pulmonary diseases in the elderly population. The larger market segment of diagnostics spirometry products will grow at a faster rate than the smaller pulmonary function testing and disposable products market, driven by an emphasis of disease prevention via early diagnosis in outpatient and alternate care settings. Check out our infographic on the market.
Owlstone Medical has signed another major collaboration agreement with a big pharma company to use its breath biopsy services. The Cambridge, UK company is partnering with AstraZeneca to to identify novel breath biomarkers for asthma and COPD.